IBBQ News and Press, Invesco Nasdaq Biotechnology ETF From 08/04/22

The investment landscape has been much more difficult for most sustainable portfolios since the fourth quarter of last year. One thing that we know is that the sustainability challenges that these stocks are connected to haven’t gone away. If anything, the economic challeng...

A convergence of technologies is set to revolutionize how physicians examine the body for signs of cancer. there is every reason to expect that future evolution of robotic endoluminal procedures could include the ability during the procedure to treat the cancer, either via ablation or...

Per capita U.S. healthcare spending went from $2,968 in 1980 to $12,531 in 2020 (both in 2020 dollars), more than a threefold increase. Amazon announced its plans to acquire primary healthcare company One Medical for $3.9 billion. I believe this deal represents the catalyst for a sign...

After a difficult first half, healthcare’s defensive capabilities are coming into question, but it outperformed the broader markets on a relative basis. The MSCI World Healthcare Index fell by 10.3% through June 30, 2022, in US dollar terms, compared to a 20.5% decline for the ...

Massive short interest buildup is like tinder for a bullish fire. Good economic news is the match for the short-covering rally. Healthcare stocks look especially good and should outperform. After several tortuous weeks of abnormal volatility and a directionless trading e...

Gilead Sciences started 2022 on a solid foot, as the original outlook for the year was quite underwhelming. This is comforting, yet the composition of the beat, driven by stronger pandemic related sales, is a bit disappointing. Amidst non-demanding valuation and traction with some...

Amgen outperformed the U.S. stock market in the last few months and also reported solid first quarter results. In the years to come, earnings per share will grow due to share buybacks as well as top line growth. Until 2030, management is expecting earnings per share to grow in the...

As companies adjust to inflation, rising interest rates, and a likely economic slowdown, investors are struggling to compute future earnings and the impact on stock valuations. Broadening the sources of stability can help diversify risk and return potential. Geopolitical risk and ...

Why the economy, practically speaking, may already be in recession. Why defensive sectors may be worth a closer look in the current environment. Market sentiment might be bearish, but that doesn't mean there aren't opportunities. Aggressive moves by central banks...

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...